Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.

Brown TA, Byrd K, Vreeland TJ, Clifton GT, Jackson DO, Hale DF, Herbert GS, Myers JW, Greene JM, Berry JS, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwel GL, Peoples GE.

Cancer Med. 2019 Aug;8(10):4678-4687. doi: 10.1002/cam4.2378. Epub 2019 Jul 5.

2.

Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.

Clifton GT, Peace KM, Holmes JP, Vreeland TJ, Hale DF, Herbert GS, Litton JK, Murthy RK, Lukas J, Peoples GE, Mittendorf Elizabeth A.

Clin Immunol. 2019 Apr;201:48-54. doi: 10.1016/j.clim.2019.02.011. Epub 2019 Feb 25.

PMID:
30817999
3.

Foot-propelled swimming kinematics and turning strategies in common loons.

Clifton GT, Biewener AA.

J Exp Biol. 2018 Oct 11;221(Pt 19). pii: jeb168831. doi: 10.1242/jeb.168831.

4.

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE.

Clin Immunol. 2018 Oct;195:28-35. doi: 10.1016/j.clim.2018.06.008. Epub 2018 Jul 17.

PMID:
30025819
5.

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.

Herbert GS, Vreeland TJ, Clifton GT, Greene JM, Jackson DO, Hardin MO, Hale DF, Berry JS, Nichol P, Yin S, Yu X, Wagner TE, Peoples GE.

Vaccine. 2018 May 31;36(23):3247-3253. doi: 10.1016/j.vaccine.2018.04.078. Epub 2018 May 1.

PMID:
29724512
6.

Augmenting mask-based lithography with direct laser writing to increase resolution and speed.

Lim MP, Guo X, Grunblatt EL, Clifton GM, Gonzalez AN, LaFratta CN.

Opt Express. 2018 Mar 19;26(6):7085-7090. doi: 10.1364/OE.26.007085.

PMID:
29609394
7.

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.

Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA.

Clin Immunol. 2018 Jul;192:6-13. doi: 10.1016/j.clim.2018.03.010. Epub 2018 Mar 21.

8.

Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.

Hardin MO, Vreeland TJ, Clifton GT, Hale DF, Herbert GS, Greene JM, Jackson DO, Berry JE, Nichols P, Yin S, Yu X, Wagner TE, Peoples GE.

Immunotherapy. 2018 Apr;10(5):373-382. doi: 10.2217/imt-2017-0114.

PMID:
29473470
9.

Comparative hindlimb myology of foot-propelled swimming birds.

Clifton GT, Carr JA, Biewener AA.

J Anat. 2018 Jan;232(1):105-123. doi: 10.1111/joa.12710. Epub 2017 Nov 3.

PMID:
29098684
10.

Cognitive Training Enhances Auditory Attention Efficiency in Older Adults.

O'Brien JL, Lister JJ, Fausto BA, Clifton GK, Edwards JD.

Front Aging Neurosci. 2017 Oct 4;9:322. doi: 10.3389/fnagi.2017.00322. eCollection 2017.

11.

Routine Pre-Treatment MRI for Breast Cancer in a Single-Payer Medical Center: Effects on Surgical Choices, Timing and Outcomes.

Vreeland TJ, Berry Iv JS, Schneble E, Jackson DO, Herbert GS, Hale DF, Martin JM, Flores M, Pattyn AR, Hata K, Clifton GT, Kirkpatrick AD, Peoples GE.

J Cancer. 2017 Jul 23;8(13):2442-2448. doi: 10.7150/jca.16738. eCollection 2017.

12.

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA.

Cancer Res. 2017 Oct 1;77(19):5374-5383. doi: 10.1158/0008-5472.CAN-16-2774. Epub 2017 Aug 17.

13.

Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development.

Berry JS, Vreeland TJ, Hale DF, Jackson DO, Trappey AF, Greene JM, Hardin MO, Herbert GS, Clifton GT, Peoples GE.

J Cancer. 2017 May 11;8(7):1255-1262. doi: 10.7150/jca.16450. eCollection 2017.

14.

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.

Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA.

Ann Surg Oncol. 2017 Aug;24(8):2161-2167. doi: 10.1245/s10434-017-5844-0. Epub 2017 Mar 17.

15.

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.

Jackson DO, Byrd K, Vreeland TJ, Hale DF, Herbert GS, Greene JM, Schneble EJ, Berry JS, Trappey AF, Clifton GT, Hardin MO, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwell GL, Peoples GE.

Oncotarget. 2017 Feb 28;8(9):15912-15923. doi: 10.18632/oncotarget.13305.

16.

Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.

Berry J, Vreeland T, Trappey A, Hale D, Peace K, Tyler J, Walker A, Brown R, Herbert G, Yi F, Jackson D, Clifton G, Peoples GE.

Expert Rev Clin Immunol. 2017 Mar;13(3):235-245. doi: 10.1080/1744666X.2016.1226132. Epub 2016 Aug 30. Review.

PMID:
27552944
17.

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.

Vreeland TJ, Clifton GT, Herbert GS, Hale DF, Jackson DO, Berry JS, Peoples GE.

Expert Rev Clin Immunol. 2016 Dec;12(12):1347-1357. Epub 2016 Jun 28. Review.

PMID:
27323245
18.

Clinical Development of the E75 Vaccine in Breast Cancer.

Clifton GT, Gall V, Peoples GE, Mittendorf EA.

Breast Care (Basel). 2016 Apr;11(2):116-21. doi: 10.1159/000446097. Epub 2016 Apr 26. Review.

19.

Peptide-Based Cancer Vaccine Strategies and Clinical Results.

Schneble E, Clifton GT, Hale DF, Peoples GE.

Methods Mol Biol. 2016;1403:797-817. doi: 10.1007/978-1-4939-3387-7_46. Review.

PMID:
27076168
20.

The development and use of the E75 (HER2 369-377) peptide vaccine.

Clifton GT, Peoples GE, Mittendorf EA.

Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5.

21.

Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial Atypia on Core Needle Biopsy to Aid in the Decision of Excision or Observation.

Berry JS, Trappey AF, Vreeland TJ, Pattyn AR, Clifton GT, Berry EA, Schneble EJ, Kirkpatrick AD, Saenger JS, Peoples GE.

J Cancer. 2016 Jan 1;7(1):1-6. doi: 10.7150/jca.12781. eCollection 2016.

22.

Adjuvant HER2/neu peptide cancer vaccines in breast cancer.

Clifton GT, Mittendorf EA, Peoples GE.

Immunotherapy. 2015;7(11):1159-68. doi: 10.2217/imt.15.81. Epub 2015 Nov 16. Review.

PMID:
26567563
23.

Critical issues in cancer vaccine trial design.

Clifton GT, Kohrt HE, Peoples GE.

Vaccine. 2015 Dec 16;33(51):7386-7392. doi: 10.1016/j.vaccine.2015.09.019. Epub 2015 Sep 19. Review.

PMID:
26392010
24.

Western and Clark's grebes use novel strategies for running on water.

Clifton GT, Hedrick TL, Biewener AA.

J Exp Biol. 2015 Apr 15;218(Pt 8):1235-43. doi: 10.1242/jeb.118745.

25.

Effect of an enhanced medical home on serious illness and cost of care among high-risk children with chronic illness: a randomized clinical trial.

Mosquera RA, Avritscher EB, Samuels CL, Harris TS, Pedroza C, Evans P, Navarro F, Wootton SH, Pacheco S, Clifton G, Moody S, Franzini L, Zupancic J, Tyson JE.

JAMA. 2014 Dec 24-31;312(24):2640-8. doi: 10.1001/jama.2014.16419.

PMID:
25536255
26.

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.

Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE.

Ann Oncol. 2014 Sep;25(9):1735-42. doi: 10.1093/annonc/mdu211. Epub 2014 Jun 6.

27.

The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.

Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE.

Immunotherapy. 2014;6(5):519-31. doi: 10.2217/imt.14.22. Review.

PMID:
24896623
28.

Treatment of complex medical emergencies in a forward deployed setting: a case of out-of-hospital cardiac arrest.

Clifton GT, Willis SL, Peterson WC.

Mil Med. 2014 Feb;179(2):e237-9. doi: 10.7205/MILMED-D-13-00335.

PMID:
24491623
29.

Commentary on medical group practice characteristics influencing inappropriate emergency department and avoidable hospitalization rates.

Clifton G.

J Ambul Care Manage. 2013 Oct-Dec;36(4):292. doi: 10.1097/JAC.0b013e3182a3e75b. No abstract available.

PMID:
24402070
30.

Neurological outcome scale for traumatic brain injury: III. Criterion-related validity and sensitivity to change in the NABIS hypothermia-II clinical trial.

McCauley SR, Wilde EA, Moretti P, Macleod MC, Pedroza C, Drever P, Fourwinds S, Frisby ML, Beers SR, Scott JN, Hunter JV, Traipe E, Valadka AB, Okonkwo DO, Zygun DA, Puccio AM, Clifton GL.

J Neurotrauma. 2013 Sep 1;30(17):1506-11. doi: 10.1089/neu.2013.2925. Epub 2013 Aug 2.

31.

Cooling strategies targeting trauma.

Dietrich WD, Povlishock JT, Clifton G, Bullock MR, Wang MY.

Ther Hypothermia Temp Manag. 2012 Dec;2(4):162-5. doi: 10.1089/ther.2012.1519. No abstract available.

PMID:
24716489
32.

Hand-sewn gastrojejunostomy using knotless unidirectional barbed absorbable suture during laparoscopic gastric bypass.

Tyner RP, Clifton GT, Fenton SJ.

Surg Endosc. 2013 Apr;27(4):1360-6. doi: 10.1007/s00464-012-2616-6. Epub 2012 Oct 24.

PMID:
23093243
33.

Cancer vaccines: should we be targeting patients with less aggressive disease?

Hale DF, Clifton GT, Sears AK, Vreeland TJ, Shumway N, Peoples GE, Mittendorf EA.

Expert Rev Vaccines. 2012 Jun;11(6):721-31. doi: 10.1586/erv.12.39. Review.

PMID:
22873128
34.

Early induction of hypothermia for evacuated intracranial hematomas: a post hoc analysis of two clinical trials.

Clifton GL, Coffey CS, Fourwinds S, Zygun D, Valadka A, Smith KR Jr, Frisby ML, Bucholz RD, Wilde EA, Levin HS, Okonkwo DO.

J Neurosurg. 2012 Oct;117(4):714-20. doi: 10.3171/2012.6.JNS111690. Epub 2012 Jul 27.

PMID:
22839656
35.

The GP2 peptide: a HER2/neu-based breast cancer vaccine.

Clive KS, Tyler JA, Clifton GT, Holmes JP, Ponniah S, Peoples GE, Mittendorf EA.

J Surg Oncol. 2012 Apr 1;105(5):452-8. doi: 10.1002/jso.21723. Review.

PMID:
22441896
36.

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE.

Cancer. 2012 May 15;118(10):2594-602. doi: 10.1002/cncr.26574. Epub 2011 Oct 11.

37.

AE37: a novel T-cell-eliciting vaccine for breast cancer.

Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE.

Expert Opin Biol Ther. 2011 Nov;11(11):1543-50. doi: 10.1517/14712598.2011.616889. Epub 2011 Sep 6. Review.

PMID:
21895539
38.

Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.

Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE.

Expert Rev Vaccines. 2011 Jun;10(6):755-74. doi: 10.1586/erv.11.59. Review.

PMID:
21692698
39.

Diffusion tensor imaging of the perforant pathway zone and its relation to memory function in patients with severe traumatic brain injury.

Christidi F, Bigler ED, McCauley SR, Schnelle KP, Merkley TL, Mors MB, Li X, Macleod M, Chu Z, Hunter JV, Levin HS, Clifton GL, Wilde EA.

J Neurotrauma. 2011 May;28(5):711-25. doi: 10.1089/neu.2010.1644. Epub 2011 Apr 27.

PMID:
21381986
40.

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.

Benavides LC, Sears AK, Gates JD, Clifton GT, Clive KS, Carmichael MG, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE.

Expert Rev Vaccines. 2011 Feb;10(2):201-10. doi: 10.1586/erv.10.167. Review.

PMID:
21332269
41.

Folate receptor α: a storied past and promising future in immunotherapy.

Clifton GT, Sears AK, Clive KS, Holmes JP, Mittendorf EA, Ioannides CG, Ponniah S, Peoples GE.

Hum Vaccin. 2011 Feb;7(2):183-90. Epub 2011 Feb 1. Review.

PMID:
21321484
42.

A review of clinical trials of hypothermia treatment for severe traumatic brain injury.

Clifton GL.

Ther Hypothermia Temp Manag. 2011;1(3):143-9. doi: 10.1089/ther.2011.0009. Epub 2011 Oct 24.

PMID:
24717043
43.

Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial.

Clifton GL, Valadka A, Zygun D, Coffey CS, Drever P, Fourwinds S, Janis LS, Wilde E, Taylor P, Harshman K, Conley A, Puccio A, Levin HS, McCauley SR, Bucholz RD, Smith KR, Schmidt JH, Scott JN, Yonas H, Okonkwo DO.

Lancet Neurol. 2011 Feb;10(2):131-9. doi: 10.1016/S1474-4422(10)70300-8. Epub 2010 Dec 17.

44.

Trends in cancer screening among Hispanic and white non-Hispanic women, 2000-2005.

Zhou J, Enewold L, Peoples GE, Clifton GT, Potter JF, Stojadinovic A, Zhu K.

J Womens Health (Larchmt). 2010 Dec;19(12):2167-74. doi: 10.1089/jwh.2009.1909. Epub 2010 Nov 1.

PMID:
21039233
45.

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.

Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, Stojadinovic A, Ponniah S, Peoples GE.

Vaccine. 2010 Nov 3;28(47):7476-82. doi: 10.1016/j.vaccine.2010.09.029. Epub 2010 Sep 19.

PMID:
20858449
46.

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S, Peoples GE.

Cancer. 2011 Feb 1;117(3):463-71. doi: 10.1002/cncr.25586. Epub 2010 Sep 15.

47.

The temporal stem in traumatic brain injury: preliminary findings.

Bigler ED, McCauley SR, Wu TC, Yallampalli R, Shah S, MacLeod M, Chu Z, Hunter JV, Clifton GL, Levin HS, Wilde EA.

Brain Imaging Behav. 2010 Dec;4(3-4):270-82. doi: 10.1007/s11682-010-9105-0.

PMID:
20835782
48.

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE.

Expert Rev Vaccines. 2010 May;9(5):519-25. doi: 10.1586/erv.10.40. Review.

PMID:
20450326
49.

Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury.

Hergenroeder GW, Moore AN, McCoy JP Jr, Samsel L, Ward NH 3rd, Clifton GL, Dash PK.

J Neuroinflammation. 2010 Mar 11;7:19. doi: 10.1186/1742-2094-7-19.

50.

The Neurological Outcome Scale for Traumatic Brain Injury (NOS-TBI): I. Construct validity.

Wilde EA, McCauley SR, Kelly TM, Weyand AM, Pedroza C, Levin HS, Clifton GL, Schnelle KP, Shah MV, Moretti P.

J Neurotrauma. 2010 Jun;27(6):983-9. doi: 10.1089/neu.2009.1194.

Supplemental Content

Loading ...
Support Center